SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

MDWD

MediWound Ltd.
BEARISH
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Traders should monitor progress of the EscharEx Phase III trial and regulatory approvals for the new NexoBrid facility as key near-term catalysts. While cash is strong, continued revenue declines and negative EBITDA suggest ongoing execution risk. The reaffirmed guidance provides some forward hope, but near-term fundamentals are weak.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$17.45
T+0 close · Mar 5, 2026 · via day close
Latest settled
−20.80%
T+60 · $13.82
Vs SPY
−32.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $17.45entry
  2. T+1 · 9mo ago −2.41%α −1.09% · $17.03
  3. T+5 · 8mo ago −4.99%α −2.75% · $16.58
  4. T+20 · 8mo ago −3.67%α +0.12% · $16.81
  5. T+60 · 6mo ago −20.80%α −32.10% · $13.82
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MediWound reported a decline in Q4 and full-year 2025 revenue, driven by lower development services due to the U.S. government shutdown and reduced product sales to Vericel. Despite higher R&D spending on the EscharEx Phase III trial, the company maintained a strong cash position of $53.6 million and reaffirmed its 2026–2028 revenue guidance. The stock remains speculative, tied to upcoming clinical and regulatory catalysts.

Key Financial Metrics

Revenue
$17.0M
-15.8% YoY
EPS
$-2.10
Guidance
$24M-$26M
maintained

Key Facts

  • Q4 2025 revenue was $1.9 million, down 67% from $5.8 million in Q4 2024
  • Full-year 2025 revenue was $17.0 million, down from $20.2 million in 2024
  • Net loss for 2025 was $23.9 million, or $2.10 per share, compared to $30.2 million, or $3.03 per share, in 2024
  • Cash balance increased to $53.6 million at year-end, up from $43.6 million, due to a $30 million registered direct offering
  • Company reaffirmed 2026 revenue guidance of $24–26 million, $32–35 million in 2027, and $50–55 million in 2028
  • EscharEx Phase III VALUE trial progressing with enrollment and interim assessment expected by end of 2026
  • Expanded NexoBrid manufacturing facility now operational, with sixfold capacity increase; regulatory approvals expected in 2026

Financial Impact

Revenue declined 15.8% YoY to $17.0 million; operating loss widened to $25.3 million from $19.4 million in 2024

revenueoperating_lossepscash_flow

Risk Factors

  • Revenue heavily impacted by U.S. government budget delays; future development revenue remains uncertain
  • EscharEx approval and commercial success are not guaranteed; clinical or regulatory setbacks could significantly impact valuation
  • High R&D spend ($14.3M in 2025) continues to drive losses despite lower SG&A

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250013

Track record

13 reports on MDWD

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +8.48% at T+60 after the May 27, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $12.90 Now $13.55 +5.04% settles Nov 20
  2. Nov 12, 20264d ago 6-K Bearish 6/10 No price data
  3. Nov 12, 20264d ago Press Release Bearish 6/10 Entry $12.97 Now $13.55 −4.47% settles Nov 19
  4. Nov 5, 202611d ago 6-K Bearish 6/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
  6. Nov 3, 202613d ago 424B5 Bearish 5/10 Entry $14.20 to $13.82 Now $13.55 +4.58% ▲ +2.68% +1.76% vs SPY
  7. Sep 22, 20267w ago Press Release Bullish 4/10 Entry $13.95 to $13.80 Now $13.55 −2.87% ▼ −1.08% +0.11% vs SPY
  8. Jun 2, 202623w ago Insider Cluster Bullish 4/10 Entry $13.76 to $14.30 Now $13.55 −1.53% ▲ +3.92% +6.89% vs SPY
  9. May 27, 202624w ago Press Release Bearish 5/10 Entry $14.33 to $13.73 Now $13.55 +5.44% ▲ +4.19% +4.66% vs SPY
  10. May 7, 202627w ago Press Release Neutral 1/10 Entry $17.27 to $16.25 Now $13.55 −21.54% ▼ −5.91% −7.41% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026